Need to Meet The Therapy Requirement Boost The Multiple Sclerosis Drugs Market

Posted on: Mar-2017 | By: 9 Dimen | Pharmaceuticals and Healthcare

Multiple sclerosis, which is a nervous system disorder, affects the brain & spinal cord. It injures the myelin sheath. Myelin sheath is the material that protects and surrounds the human nerve cells. This injury inhibits messages between the body and brain resulting in indications of multiple sclerosis. Few of the important signs of multiple sclerosis include memory & thinking issues, difficulty in synchronizing and balancing the body, visual disturbances, and muscle weakness.

More than men, women are affected by multiple sclerosis. It is mostly observed in an age group of 20–40. Multiple sclerosis is classified into four different types, namely, progressive-relapsing multiple sclerosis, relapsing-remitting multiple sclerosis, primary-progressive multiple sclerosis, and secondary-progressive multiple sclerosis. The most common type of the disorder is the relapsing-remitting multiple sclerosis. The secondary-progressive type of disease is linked to the early phase of the relapsing-remitting disease. Progressive-relapsing multiple sclerosis is rarely found.

The rising incidence of multiple sclerosis disease, the high unmet requirement of drugs for treating the disease, changing lifestyle of the population, technological advancements, rising expenditure by the public and private organization in research & development, and wide R&D pipelines are few of the important factors that are fueling the global market for multiple sclerosis drugs. Apart from this, the growing study in the multiple sclerosis field to invent novel therapies to treat people may also propel the market growth in the near future.

However, the expiry of patents of important drugs is a major factor that can impede the growth of the global market. Additionally, the strict regulatory obstacles may also restrict the growth of the market for multiple sclerosis drugs. Enhancement in biomedical science may generate prospects for the global market. Also, the rising acquisitions and mergers among manufacturing firms and speeding launch of new product are few of the key trends for the global multiple sclerosis drugs market.